Template:Growth factor receptor modulators: Difference between revisions
From WikiMD's Wellness Encyclopedia
en>Whywhenwhohow add fruquintinib |
m 1 revision imported |
||
| (One intermediate revision by the same user not shown) | |||
| Line 5: | Line 5: | ||
| bodyclass = hlist | | bodyclass = hlist | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| border = {{{border|}}}<!-- for embedding in other navbox templates --> | | border = {{{border|}}}<!--for embedding in other navbox templates--> | ||
| group1 = [[Angiopoietin receptor|Angiopoietin]] | | group1 = [[Angiopoietin receptor|Angiopoietin]] | ||
| Line 32: | Line 32: | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
<!-- Breakdown of ErbBRs and ligands: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570895/table/T1/ --> | <!--Breakdown of ErbBRs and ligands: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570895/table/T1/--> | ||
| group1 = [[Epidermal growth factor receptor|EGF<br /><small>(ErbB1/HER1)</small>]] | | group1 = [[Epidermal growth factor receptor|EGF<br /><small>(ErbB1/HER1)</small>]] | ||
| Line 47: | Line 47: | ||
* ''Kinase inhibitors:'' [[Afatinib]] | * ''Kinase inhibitors:'' [[Afatinib]] | ||
* [[AG-490]] | |||
* [[Agerafenib]] | * [[Agerafenib]] | ||
* [[Brigatinib]] | * [[Brigatinib]] | ||
| Line 79: | Line 80: | ||
* [[Pertuzumab]] | * [[Pertuzumab]] | ||
* [[Trastuzumab]] | * [[Trastuzumab]] | ||
* [[Trastuzumab duocarmazine]] | * [[Trastuzumab duocarmazine]] | ||
* [[Trastuzumab emtansine]] | * [[Trastuzumab emtansine]] | ||
* ''Kinase inhibitors:'' [[Afatinib]] | * ''Kinase inhibitors:'' [[Afatinib]] | ||
* [[AG-490]] | |||
* [[Lapatinib]] | * [[Lapatinib]] | ||
* [[Mubritinib]] | * [[Mubritinib]] | ||
| Line 110: | Line 111: | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
<!-- Breakdown of FGFRs and ligands: https://books.google.com/books?id=CNwLlih2C60C&lpg=PA216&pg=PA216 --> | <!--Breakdown of FGFRs and ligands: https://books.google.com/books?id=CNwLlih2C60C&lpg=PA216&pg=PA216--> | ||
| group1 = [[Fibroblast growth factor receptor 1|FGFR1]] | | group1 = [[Fibroblast growth factor receptor 1|FGFR1]] | ||
| Line 133: | Line 134: | ||
* ''Antibodies:'' [[Aprutumab]] | * ''Antibodies:'' [[Aprutumab]] | ||
* [[Aprutumab ixadotin]] | * [[Aprutumab ixadotin]] | ||
| group3 = [[Fibroblast growth factor receptor 3|FGFR3]] | | group3 = [[Fibroblast growth factor receptor 3|FGFR3]] | ||
| Line 166: | Line 165: | ||
| group5 = [[Hepatocyte growth factor receptor|HGF (c-Met)]] | | group5 = [[Hepatocyte growth factor receptor|HGF (c-Met)]] | ||
| list5 = | | list5 = | ||
* ''Agonists'': | * ''Agonists'': [[Hepatocyte growth factor]] | ||
* ''Potentiators:'' [[Dihexa|Dihexa (PNB-0408)]] | * ''Potentiators:'' [[Dihexa|Dihexa (PNB-0408)]] | ||
| Line 282: | Line 280: | ||
* ''Kinase inhibitors:'' [[Agerafenib]] | * ''Kinase inhibitors:'' [[Agerafenib]] | ||
* [[Axitinib]] | * [[Axitinib]] | ||
* [[Crenolanib]] | * [[Crenolanib]] | ||
| Line 420: | Line 417: | ||
* [[7,8,2'-Trihydroxyflavone|7,8,2'-THF]] | * [[7,8,2'-Trihydroxyflavone|7,8,2'-THF]] | ||
* [[7,8,3'-Trihydroxyflavone|7,8,3'-THF]] | * [[7,8,3'-Trihydroxyflavone|7,8,3'-THF]] | ||
* [[Amitriptyline]]<!-- Weak and highly non-selective --> | * [[Amitriptyline]]<!--Weak and highly non-selective--> | ||
* [[Brain-derived neurotrophic factor|BDNF]] | * [[Brain-derived neurotrophic factor|BDNF]] | ||
* [[BNN-20]] | * [[BNN-20]] | ||
* [[Deoxygedunin]] | * [[Deoxygedunin]] | ||
* [[Deprenyl]] | * [[Deprenyl]] | ||
* [[Diosmetin]]<!-- Weak --> | * [[Diosmetin]]<!--Weak--> | ||
* [[DMAQ-B1]] | * [[DMAQ-B1]] | ||
* [[HIOC]] | * [[HIOC]] | ||
| Line 479: | Line 476: | ||
}} | }} | ||
| group13 = [[Vascular endothelial growth factor receptor|VEGF]]<!-- two receptors: VEGFR1 (FLT1R), VEGFR2 (KDR) --> | | group13 = [[Vascular endothelial growth factor receptor|VEGF]]<!--two receptors: VEGFR1 (FLT1R), VEGFR2 (KDR)--> | ||
| list13 = | | list13 = | ||
* ''Agonists:'' [[Placental growth factor|Placental growth factor (PGF)]] | * ''Agonists:'' [[Placental growth factor|Placental growth factor (PGF)]] | ||
| Line 493: | Line 490: | ||
* [[Cabozantinib]] | * [[Cabozantinib]] | ||
* [[Cediranib]] | * [[Cediranib]] | ||
* [[Lapatinib]] | * [[Lapatinib]] | ||
* [[Lenvatinib]] | * [[Lenvatinib]] | ||
| Line 541: | Line 537: | ||
* ''Additional growth factor receptor modulators:'' [[Cerebrolysin]] (neurotrophin mixture) | * ''Additional growth factor receptor modulators:'' [[Cerebrolysin]] (neurotrophin mixture) | ||
| below = | |||
;See also | |||
: ''[[Template:Receptor modulators|Receptor/signaling modulators]]'' | |||
: ''[[Template:Signaling peptide/protein receptor modulators|Signaling peptide/protein receptor modulators]]'' | |||
: ''[[Template:Cytokine receptor modulators|Cytokine receptor modulators]]'' | |||
}}<noinclude> | }}<noinclude> | ||
| Line 546: | Line 548: | ||
[[Category:Drug templates by receptor, channel, or pump]] | [[Category:Drug templates by receptor, channel, or pump]] | ||
</noinclude> | </noinclude> | ||
{{no-index-template}} | |||
Latest revision as of 19:03, 8 March 2025
